Copyright
©The Author(s) 2023.
World J Clin Cases. Jun 16, 2023; 11(17): 3932-3948
Published online Jun 16, 2023. doi: 10.12998/wjcc.v11.i17.3932
Published online Jun 16, 2023. doi: 10.12998/wjcc.v11.i17.3932
Ref. | Type of study | Modality-ies studied | Summary of key points of each study |
[2] | Systematic review/meta-analysis | LRT systems | Liver failure pathophysiology involves immune system over-activation and overproduction of proinflammatory cytokines, resulting in multiple-organ failure; reducing cytokine levels and thus correcting the dysregulation of the immune system is the pathophysiologic base of the application of LRT systems |
Plasma exchange | The best currently available LRT system in ACLF regarding 3-mo OS | ||
[9] | Review | Continuous renal replacement therapy | It has indication for initiation of when ammonia is more than × 3 the uln, or more than 200 µmoles/L or when severe encephalopathy occurs |
[10] | Review | Continuous renal replacement therapy | It has a role in the maintenance of circulatory, acid-base, and electrolyte balance during the pro-, peri-, and post-LT periods. It facilitates control of fluid balance and avoidance of volume overload/of peripheral edemas-ascites in patients with ALF and ACLF |
[11] | Guidelines | Plasma exchange | It improves transplant-free survival in ALF, and modulates immune dysregulation; patients with early treatment initiation that will not undergo LT may benefit most |
[19] | Review | Adsorption therapies | They are delivered either by direct hemoperfusion or by plasma separation and subsequent plasma perfusion |
Direct hemoperfusion (Cytosorb) | It reduces levels of plasma bilirubin, ammonia, bile acids, and C-reactive protein and alters the immune response by absorbing proinflammatory cytokines; IL-6 has been identified as one of its main therapeutic targets; it presents high safety profile and easy application; indications, endpoints, effect on mortality and detection of which patients receive benefit from its use remain to be elucidated | ||
[24] | Review | Single-pass albumin dialysis | Dialysate’s ideal albumin concentration and flow rate are not standardized while there are no commercially available albumin-containing Continuous renal replacement therapy fluids. Metabolic disarrangements and loss of antibiotics have been observed |
[30] | Clinical study | High-volume hemofiltration | An inexpensive and effective method that can be performed in every ICU or HDU, requiring no special equipment. Increased ultrafiltration rates enhance the elimination of ammonia |
[35] | Clinical study | High Cut-off membranes | Cytokine and toxin removal by these membranes may represent a promising intervention in ALF and ACLF |
[36] | Review | Adsorption therapies | They are delivered either as stand-alone or in combination with other extracorporeal modalities; the evidence to support their routine use is still conflicting and insufficient. May be of utmost benefit when applied early in the course, for an adequate duration, and frequently repeated until hemodynamic stability is achieved; they require carefully monitoring of drug levels, supplemented with additional doses as needed |
[38] | Review | Adsorption therapies | They have been used with positive effects in chronic dialysis and chronic liver disease |
Direct hemoperfusion (Cytosorb) | Ιt removes molecules up to 55 kDa | ||
[43] | Systematic review/meta-analysis | Double plasma molecular absorption system | It combines two resins that remove macromolecules, medium-sized molecules, and toxins bound to plasma proteins, bilirubin, bile acids, ammonia, phenol, mercaptan, and inflammatory molecules |
[44] | Clinical study | Double plasma molecular absorption system | It is frequently combined with Plasma exchange therapy, to overcome loss of for albumin and coagulation factors, with promising results on survival rates |
[48] | Randomized controlled study | Molecular adsorbent recirculating system | It removes albumin-bound molecules and decreases the plasma concentrations of bilirubin, ammonia, creatinine, urea, and cytokines. It has good safety profile |
[49] | Review | Molecular adsorbent recirculating system | Recirculation of albumin dialysate restricts albumin loss; under certain circumstances and indications, it has been associated with hemodynamic and clinical improvement at patients with liver disease; dose adjustments and therapeutic drug monitoring, especially for low protein-bound antibiotics, is required |
[50] | Clinical study | Molecular adsorbent recirculating system | Expensive method, application in selected centers, but when compared to standard medical therapy alone it was found more cost-effective |
[52,57] | Review, Clinical study | PROMETHEUS | It performs albumin dialysis. It removes bilirubin, ammonia, creatinine, bile acids, amino acids, cytokines and is associated with a small reduction in plasma concentration of albumin; it was associated with improvement in HE |
[54] | Randomized controlled study | PROMETHEUS | It presents good safety profile and good hemodynamic tolerance |
[67] | Randomized controlled study | PROMETHEUS | Favorable effect on patients’ subgroups such as those with more severe liver disease (MELD score > 30) and with type 1 HRS |
[69] | Randomized controlled study | Single-pass albumin dialysis | It is inexpensive, apart from the cost of albumin, and requires no special center for its application; it performs albumin dialysis and removes bilirubin, bile acids, urea and creatinine |
[76] | Review | Coupled plasma filtration adsorption | It combines plasma separation, adsorption and convection, with no loss of albumin or coagulation factors; it can effectively remove bilirubin, tryptophan, phenols, bile acids, cytokines |
[77] | Randomized controlled study | Coupled plasma filtration adsorption | It cannot be performed in patients with septic shock |
[87] | Review | Plasma exchange | It improves 1- and 3-mo survival in nontransplanted patients. More pronounced effect and high level of evidence for high volume plasma exchange |
[93] | Review | Plasma exchange | It removes cytokines and albumin-bound toxins, and replaces plasma proteins; it effectively suppresses the inflammatory cascade of liver failure, while substituting clotting factors and correcting coagulation disorders; relatively expensive, it presents transfusion related side effects and cost |
- Citation: Papamichalis P, Oikonomou KG, Valsamaki A, Xanthoudaki M, Katsiafylloudis P, Papapostolou E, Skoura AL, Papamichalis M, Karvouniaris M, Koutras A, Vaitsi E, Sarchosi S, Papadogoulas A, Papadopoulos D. Liver replacement therapy with extracorporeal blood purification techniques current knowledge and future directions. World J Clin Cases 2023; 11(17): 3932-3948
- URL: https://www.wjgnet.com/2307-8960/full/v11/i17/3932.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i17.3932